Zhejiang Garden Biopharmaceutical (300401.SZ) forecasts that its net profit for the first three quarters will be between 2.32 billion and 2.62 billion yuan, representing an increase of 55.77% to 75.92%.

Zhejiang Garden Biopharmaceutical (300401.SZ) disclosed its performance forecast for the first three quarters of 2024, with the company expecting a net profit attributable to shareholders of the listed company of 2.32 billion to 2.62 billion yuan, an increase of 55.77% - 75.92% year-on-year. After deducting non-recurring gains and losses, the net profit is expected to be 1.92 billion to 2.22 billion yuan, an increase of 44.39% - 66.96% year-on-year. The main reasons for the change in the company's performance during the reporting period are: an increase in operating income and gross profit in the vitamin sector. In addition, the company's first batch of employee shareholding plan lock-up period and additional lock-up period expired in 2022, resulting in a decrease in share-based payment expenses compared to the same period last year. The impact of non-recurring gains and losses on net profit is expected to be approximately 40 million yuan, mainly due to the completion of relocation work by subsidiaries and the confirmation of related asset disposal gains.